TABLE 2.
| Age (y) | 65.0±12.1 |
| Sex | |
| Male | 13 (86.7) |
| Female | 2 (13.3) |
| BMI | |
| Obesity | 5 (33.3) |
| Race | |
| White | 11 (73.3) |
| Black | 3 (20.0) |
| Asian or Pacific Islander | 1 (6.7) |
| Smoking | |
| Never smoked | 7 (46.7) |
| Quit smoking | 8 (53.3) |
| Hypercholesterolemia | 12 (80.0) |
| Hypertension | 15 (100) |
| Family history of CAD | 5 (33.3) |
| Diabetes | 6 (40.0) |
| Bradyarrhythmias or complete heart block | 0 (0) |
| Atrial tachyarrhythmia | 1 (6.7) |
| Ventricular tachyarrhythmia or fibrillation | 0 (0) |
| Peripheral vascular disease | 2 (13.3.) |
| Chronic obstructive pulmonary disease | 2 (13.3.) |
| Congestive heart failure | 3 (20.0) |
| Uncontrolled hypertension | 2 (13.3) |
| CABG | 10 (66.7) |
| PTCA | 12 (80.0) |
| Coronary stent | 10 (66.7) |
| Rotational atherectomy | 1 (6.7) |
| Angiojet thrombolysis catheter | 1 (6.7) |
| Spinal cord stimulator | 0 (0) |
| External counter pulsation | 3 (20.0) |
| Medications | |
| Aspirin | 14 (100) |
| Clopidogrel | 7 (50.0) |
| Warfarin | 1 (7.1) |
| Statin | 14 (100) |
| β-Blocker | 11 (78.6) |
| Calcium antagonist | 6 (42.9) |
| Nitrate | 11 (78.6) |
| Ranolazine | 5 (35.7) |
| ACE-I/ARB | 7 (50.0) |
a
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; CABG=coronary artery bypass graft; CAD = coronary artery disease; PTCA = percutaneous transluminal coronary angioplasty.
b
Data are presented as mean ± SD or as No. (percentage).
c
N = 15; n = 14 for medications.